[{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Margetuximab","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Retifanlimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"MacroGenics","amount2":0.90000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.90000000000000002,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Teplizumab","moa":"T-cell surface glycoprotein CD3 epsilon chain","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"MacroGenics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.40000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Provention Bio","highestDevelopmentStatusID":"15","companyTruncated":"MacroGenics \/ Provention Bio"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Sagard Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Retifanlimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"MacroGenics","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.20999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Sagard Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"MacroGenics \/ Sagard Healthcare"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Margetuximab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Carboplatin","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Carboplatin","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Cisplatin","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0.90000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.90000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Margetuximab","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Margetuximab","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Enoblituzumab","moa":"CD276 antigen","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Enoblituzumab","moa":"||CD276 antigen","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Vobramitamab Duocarmazine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Vobramitamab Duocarmazine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"MacroGenics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"MGC018","moa":"B7 homolog 3 (CD276)","graph1":"Oncology","graph2":"Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ MacroGenics","highestDevelopmentStatusID":"8","companyTruncated":"MacroGenics \/ MacroGenics"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"||T cell surface glycoprotein CD3 | Interleukin-3 receptor subunit alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"T cell surface glycoprotein CD3 | Interleukin-3 receptor subunit alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"T cell surface glycoprotein CD3 | Interleukin-3 receptor subunit alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"T cell surface glycoprotein CD3 | Interleukin-3 receptor subunit alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"MGA012","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lorigerlimab","moa":"||Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"T cell surface glycoprotein CD3 | Interleukin-3 receptor subunit alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"MacroGenics","amount2":1.46,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.46,"dosageForm":"Oral","sponsorNew":"MacroGenics \/ Zai Lab","highestDevelopmentStatusID":"4","companyTruncated":"MacroGenics \/ Zai Lab"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"MacroGenics","amount2":0.58999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0.58999999999999997,"dosageForm":"Oral","sponsorNew":"MacroGenics \/ MacroGenics","highestDevelopmentStatusID":"4","companyTruncated":"MacroGenics \/ MacroGenics"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"MacroGenics","amount2":2.2000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":2.2000000000000002,"dosageForm":"Oral","sponsorNew":"MacroGenics \/ MacroGenics","highestDevelopmentStatusID":"4","companyTruncated":"MacroGenics \/ MacroGenics"},{"orgOrder":0,"company":"MacroGenics","sponsor":"TerSera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"Margetuximab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"MacroGenics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ TerSera Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"MacroGenics \/ TerSera Therapeutics"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0.91000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.91000000000000003,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"MacroGenics","sponsor":"MacroGenics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lorigerlimab","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ MacroGenics","highestDevelopmentStatusID":"8","companyTruncated":"MacroGenics \/ MacroGenics"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lorigerlimab","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"MacroGenics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Enoblituzumab","moa":"CD276 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ MacroGenics","highestDevelopmentStatusID":"8","companyTruncated":"MacroGenics \/ MacroGenics"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lorigerlimab","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Vobramitamab Duocarmazine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Immunogen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"IMGC936","moa":"Cellular disintegrin-related protein (ADAM9)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ MacroGenics","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ MacroGenics"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Vobramitamab Duocarmazine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MGD024","moa":"CD3\/123","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"MGD024","moa":"CD3\/123","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":1.76,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.76,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Gilead Sciences"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MGD013","moa":"Programmed cell death protein 1 | Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MGD013","moa":"Programmed cell death protein 1 | Lymphocyte activation gene 3 protein","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lorigerlimab","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"National Institute of Allergy and Infectious Diseases | National Institutes of Health | Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MGD020","moa":"CD80\/CD112","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ National Institute of Allergy and Infectious Diseases | National Institutes of Health | Department of Health and Human Services","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ National Institute of Allergy and Infectious Diseases | National Institutes of Health | Department of Health and Human Services"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MGC026","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MGC028","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by MacroGenics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Zynyz (retifanlimab) is a humanized monoclonal antibody targeting programmed death receptor-1, originally developed by MacroGenics.

                          Product Name : Zynyz

                          Product Type : Antibody

                          Upfront Cash : $70.0 million

                          June 10, 2025

                          Lead Product(s) : Retifanlimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Sagard Healthcare

                          Deal Size : $210.0 million

                          Deal Type : Agreement

                          blank

                          02

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          December 12, 2024

                          Lead Product(s) : Lorigerlimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 09, 2024

                          Lead Product(s) : MGC028

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Under the agreement, TerSera will acquire global rights to Margenza (margetuximab) from MacroGenics. It is indicated for the treatment of HER2-positive breast cancer.

                          Product Name : Margenza

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          October 22, 2024

                          Lead Product(s) : Margetuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : TerSera Therapeutics

                          Deal Size : $75.0 million

                          Deal Type : Acquisition

                          blank

                          05

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Under the license agreement, MacroGenics will focus on the development of Zynyz (retifanlimab), which is being evaluated in the late-stage trial studies for treating Squamous Cell Anal Carcinoma.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : $150.0 million

                          July 30, 2024

                          Lead Product(s) : Retifanlimab,Carboplatin,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Incyte Corporation

                          Deal Size : $905.0 million

                          Deal Type : Licensing Agreement

                          blank

                          06

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : MGC018 (vobramitamab duocarmazine) is an ADC which works by targeting B7-H3, is being investigated in patients with metastatic castration-resistant prostate cancer.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          March 04, 2024

                          Lead Product(s) : Vobramitamab Duocarmazine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 05, 2024

                          Lead Product(s) : MGC026

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          January 29, 2024

                          Lead Product(s) : MGC018

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Georgetown University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : Enoblituzumab

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Recipient : Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          August 28, 2023

                          Lead Product(s) : Enoblituzumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 08, 2023

                          Lead Product(s) : Lorigerlimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank